0.19
0.00%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Theralase Technologies
Its shares trade on TSX Venture under the ticker TLT.V. It has been listed since 2 November 2004. In the fiscal year to 31 December 2025, it reported revenue of C$816,468 and a net loss of C$4.1m. At that date it held total assets of C$3.5m and shareholders' equity of C$1.8m.
Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in East York, Ontario. The company went IPO on 2004-11-02. The firm operates through two divisions: Therapeutic Laser Technology (TLT) division and Photo Dynamic Therapy (PDT) division. The TLT division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology is used for healing a range of nerve, muscle and joint conditions, including arthritis, osteoarthritis and wounds. The PDT division develops PDCs and activates them with laser technology to destroy specifically targeted cancers and bacteria. Its TLC-2000 Biofeedback Therapeutic Laser Technology possesses Cell Sensing technology that senses and targets injured tissue. The company is also developing TLC-1000 therapeutic medical laser system. The company is developing TLC-3000 medical laser system for the treatment of a range of cancers.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 2 Nov 2004
- Website
- theralase.com ↗
Leadership
Pay as last reported
- Mr. Roger Dumoulin-WhiteChairman of the Board, President, Chief Executive Officer, since 2004C$612,330
- Ms. Kristina HacheyChief Financial Officer, Director, since 2004C$381,398
- Dr. Arkady MandelChief Scientific Officer, Director, since 2018C$431,398
- Mr. Guy AndersonIndependent DirectorC$131,398
- Mr. Randy BruderIndependent DirectorC$131,398
- Dr. Kaouthar LbiatiIndependent DirectorC$107,118
- Mr. Matthew PerratonIndependent DirectorC$131,398
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Theralase Technologies Inc is a leading innovator in the field of medical laser technology. Their extensive research and development efforts have resulted in a strong portfolio of intellectual property, including a wide range of patents.
- The company's laser systems offer various applications and benefits, such as pain management, tissue regeneration, and therapeutic treatments. These cutting-edge technologies provide Theralase with a competitive advantage and contribute to its reputation as a leader in the industry.
Weaknesses
- One weakness to consider is Theralase's dependence on a relatively small number of key customers. This concentration of revenue increases the company's vulnerability to fluctuations in customer demand or potential loss of these key accounts.
- Additionally, Theralase faces challenges in terms of market awareness and adoption of their advanced laser systems. The medical field may be slow to embrace new technologies, requiring substantial efforts in education and marketing to overcome resistance and penetrate the market effectively.
Opportunities
- With the increasing focus on non-invasive and drug-free treatments, Theralase has an opportunity to expand its market share. The growing demand for alternative therapies and the potential benefits of laser-based treatments make it an opportune time for the company to develop and commercialize new products.
- Furthermore, advancements in healthcare infrastructure and ongoing medical research present potential collaborations for Theralase. By partnering with leading medical institutions or healthcare providers, they can enhance their credibility, access larger customer bases, and accelerate the adoption of their technologies.
Threats
- The competitive landscape poses a threat to Theralase as other companies may develop similar laser technologies or alternative treatment methods. Keeping ahead of technological advancements and protecting their intellectual property is crucial to maintain a competitive edge.
- Additionally, regulatory requirements and compliance can pose challenges for Theralase in terms of obtaining necessary approvals and certifications for their products. Delays in regulatory processes or increased regulations may negatively impact their time to market and limit their growth opportunities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.